GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunomedics Inc (NAS:IMMU) » Definitions » Cyclically Adjusted Revenue per Share

Immunomedics (Immunomedics) Cyclically Adjusted Revenue per Share : $0.00 (As of Jun. 2020)


View and export this data going back to 1990. Start your Free Trial

What is Immunomedics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Immunomedics's adjusted revenue per share for the three months ended in Jun. 2020 was $0.089. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Jun. 2020.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-05), Immunomedics's current stock price is $87.86. Immunomedics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2020 was $0.00. Immunomedics's Cyclically Adjusted PS Ratio of today is .


Immunomedics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Immunomedics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunomedics Cyclically Adjusted Revenue per Share Chart

Immunomedics Annual Data
Trend Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Dec19
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immunomedics Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunomedics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Immunomedics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunomedics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunomedics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Immunomedics's Cyclically Adjusted PS Ratio falls into.



Immunomedics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Immunomedics's adjusted Revenue per Share data for the three months ended in Jun. 2020 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2020 (Change)*Current CPI (Jun. 2020)
=0.089/108.7673*108.7673
=0.089

Current CPI (Jun. 2020) = 108.7673.

Immunomedics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201009 0.020 92.162 0.024
201012 0.013 92.474 0.015
201103 0.015 94.283 0.017
201106 0.147 95.235 0.168
201109 0.015 95.727 0.017
201112 0.390 95.213 0.446
201203 0.013 96.783 0.015
201206 0.013 96.819 0.015
201209 0.014 97.633 0.016
201212 0.011 96.871 0.012
201303 0.022 98.209 0.024
201306 0.016 98.518 0.018
201309 0.066 98.790 0.073
201312 0.014 98.326 0.015
201403 0.014 99.695 0.015
201406 0.013 100.560 0.014
201409 0.012 100.428 0.013
201412 0.011 99.070 0.012
201503 0.013 99.621 0.014
201506 0.026 100.684 0.028
201509 0.008 100.392 0.009
201512 0.007 99.792 0.008
201603 0.009 100.470 0.010
201606 0.010 101.688 0.011
201609 0.008 101.861 0.009
201612 0.004 101.863 0.004
201703 0.012 102.862 0.013
201706 0.006 103.349 0.006
201709 0.006 104.136 0.006
201712 0.004 104.011 0.004
201803 0.003 105.290 0.003
201806 0.002 106.317 0.002
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.001 108.420 0.001
202003 0.000 108.902 0.000
202006 0.089 108.767 0.089

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Immunomedics  (NAS:IMMU) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Immunomedics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Immunomedics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunomedics (Immunomedics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunomedics Inc (NAS:IMMU) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
300 The American Road, Morris Plains, NJ, USA, 07950
Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.
Executives
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Peter Barton Hutt director
Charles M Baum director C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Venbio Select Advisor Llc director, 10 percent owner, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh director, 10 percent owner, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Harout Semerjian director, officer: President and CEO 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950
Kurt J. Andrews officer: Chief Human Resources Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Jared Freedberg officer: General Counsel 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Usama Malik officer: Chief Business Officer & CFO 300 THE AMERICAN WAY MORRIS PLAINS NJ 07950
Brendan Delaney officer: Chief Commerical Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Lorettta M Itri officer: Chief Medical Officer

Immunomedics (Immunomedics) Headlines

From GuruFocus

Immunomedics to Participate in Upcoming Healthcare Conferences

By Marketwired Marketwired 09-02-2020

Immunomedics: A Solid Cancer Research Play

By Ishan Majumdar Ishan Majumdar 07-08-2020